Summary: GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European…
Global Market
-
-
Global Market
MHRA Grants Marketing Authorisation for Global Blood Therapeutics’s Oxbryta (Voxelotor)
by adminSummary: Voxelotor is the first medicine in Britain to directly inhibit sickle haemoglobin polymerisation Global…
-
ChemIntelligenceGlobal Market
Boehringer Ingelheim, Evotec and BioMérieux Launch Aurobac, a joint venture to fight Antimicrobial Resistance
by adminSummary : Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE…
-
Summary : Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing…
-
ChemIntelligenceGlobal MarketU.S FDA
Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure
by adminSummary : First and only nitric oxide generator and delivery system indicated for the treatment…
-
IndiaPatent infringement
Panacea Biotec Files Suit against Sanofi for Patent Infringement for EasySix Vaccine
by adminSummary : Panacea Biotec on Monday said it has filed a suit before the Delhi…
-
Global MarketMerck & CoU.S FDA
Merck Scores FDA Approval for Vaxneuvance ( Pneumococcal 15-valent conjugate vaccine) for Ages 6 Weeks through 17 Years
by adminSummary : The FDA today approved the pneumococcal 15-valent conjugate vaccine for the prevention of…
-
Global MarketIntellectual Property (IP)Johnson&JohnsonPatents
Johnson & Johnson, Momenta Pharma File Patent Infringement Lawsuit Against Natco, Mylan in US for Glatiramer Acetate Injection.
by adminSummary : Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents…
-
Global MarketSanofi Inc.U.S FDA
FDA Approves Dupixent®(Dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
by adminSummary : Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly…
-
Global Market
Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy
by adminSynopsis : Halozyme (NASDAQ: HALO) (“Halozyme”) today announced the commercial launch of TLANDO™ (testosterone undecanoate),…
Newer Posts